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ABSTRACT
Background: Esophageal cancer is one of the most deadly malignancies worldwide and
esophageal squamous cell carcinoma (ESCC) is the most frequent type.
Methods: We identified up-regulated genes from gene expression profiles of HKESC-4
cell line, its parental tumor tissues, non-tumoral esophageal epithelia and lymph nodes
with metastatic carcinoma using Human Genome U133 Plus 2.0 microarray.
Results: Four genes [High-mobility group AT-hook 2 (HMGA2), paternally expressed 10
(PEG10), SH3 and multiple ankyrin repeat domains 2 (SHANK2) and WNT1 inducible
signaling pathway protein 3 (WISP3)] were selected for further validation with real-time
quantitative polymerase chain reaction (qPCR) in a panel of ESCC cell lines and clinical
specimens. HMGA2 was found to be overexpressed in the panel of ESCC cell lines
tested. By using immunohistochemistry, HMGA2 was found to be up-regulated in 70% of
ESCC tissues (21 out of 30 cases).
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Conclusion: This study demonstrates successful use of gene microarray to identify and
reveal HMGA2 as a novel and consistently overexpressed gene in ESCC cell lines and
clinical samples.
Keywords: Esophageal cancer; microarray; HMGA2; PEG10; SHANK2; WISP3.
1. INTRODUCTION
Esophageal cancer ranks fifth as the most common cause of cancer-related deaths in men
worldwide, causing about 400,000 deaths annually [1]. The incident rate is higher in
Southern and Eastern Africa and Eastern Asia when compared to Western and Middle Africa
and Central America [1]. This cancer comprises two major types, namely esophageal
squamous cell carcinoma (ESCC) and adenocarcinoma, the former is more common and
contributes to about 90% of cases in high-risk regions [1]. Patients with ESCC usually have
poor prognosis largely because of late diagnosis of the disease [2]. Despite advances in
surgical techniques combined with various treatment modalities, such as radiotherapy and
chemotherapy, the overall 5-year survival rate remains at 20-30% [3]. To alleviate this
clinical situation, the development of new treatment modalities, diagnostic technologies and
preventative measures is required, which cannot be accomplished without understanding the
underlying mechanisms of esophageal carcinogenesis. The development of gene microarray
technology allows comprehensive comparison of gene expression profiles in various
pathophysiological processes, such as enabling the comparison of gene profiles between
cancer and normal conditions. In the present study, we took advantage of this technology to
identify differentially expressed genes in cancerous and non-cancerous conditions in
esophagus, followed by further validation for the involvement of these genes in ESCC.
2. MATERIALS AND METHODS
2.1 HKESC-4 Cell Line and Clinical Specimens for Microarray
HKESC-4, a human ESCC cell line of Chinese origin, was established previously in our
laboratory and the culture conditions for this cell line were as described elsewhere [4].
Cultured HKESC-4 cells were harvested at 80% confluency at passage 30 for extracting
RNA. Parental tumoral tissue (T), from which HKESC-4 cell line was derived, and its
corresponding non-tumoral epithelium (N) and lymph node containing metastatic carcinoma
(LN) were isolated during esophagectomy and snap-frozen until their use for RNA extraction.
The extracted RNA of the cell line (HKESC-4) and clinical specimens (T, N and LN) was
subjected to gene microarray. Consent regarding the use of clinical specimens for this study
was obtained from Institutional Review Board of The University of Hong Kong/Hospital
Authority Hong Kong West Cluster (HKU/HA HKW IRB).
2.2 Clinical Tissues and ESCC Cell Lines for Quantitative Real-Time
Polymerase Chain Reaction (qPCR)
In addition to the clinical specimens for gene microarray as mentioned above, three non-
tumoral tissues were obtained from esophageal epithelium at least 5 cm away from the
tumor of other patients during surgical resection (Non-T). Apart from HKESC-4 cell line,
HKESC-1, HKESC-2, HKESC-3 and SLMT-1 cell lines were included and used as described
elsewhere [4-6]. These cells were cultured in minimal essential medium (Invitrogen,
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Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen) and 1%
penicillin-streptomycin. Cell cultures were maintained in a humidified incubator at 37oC
containing 5% carbon dioxide (CO2). Monolayer cells at 80% confluency were harvested andused for RNA extraction.
2.3 RNA Extraction for qPCR
RNA extraction was performed as described [7]. In brief, 1 ml TRIzol reagent (Invitrogen)
was used to lyse tissues or cells for RNA extraction. Chloroform was used for phase
separation. After centrifugation, the upper aqueous phase with RNA was collected and
transferred to RNase-free tubes containing 0.5 ml isopropyl alcohol for RNA precipitation.
RNA pellets were then washed with 75% RNase-free ethanol. Finally, RNA pellets were
dissolved in RNase-free water. DNase I digestion was performed before the concentration of
RNA was determined by measuring its absorbance at 260 nm and A260:A280 ratio.
2.4 Gene Microarray
RNA of HKESC-4 cells and clinical specimens were subjected to gene expression profiling
using GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA).
This GeneChip enables the analysis of over 47,000 human transcripts and variants. The
whole procedure of RNA quality control, microarray labeling, GeneChip hybridization and
data acquisition was performed at the Genome Research Centre, The University of Hong
Kong, Hong Kong, PRC under standardized condition. The statistical analysis to identify
differentially expressed genes was performed using MicroArray Suite software (Affymetrix).
2.5 Synthesis of Complementary DNA (cDNA)
RNA was reverse-transcribed into cDNA using High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Invitrogen), according to the manufacturer’s protocol. Briefly,
DNase-treated RNA was diluted with RNase-free water to reach a final concentration of 250
ng in 10 μl. Diluted RNA was then mixed with 2 μl 10X RT buffer, 0.8 μl 25X dNTP Mix (100
mM), 2 μl 10X RT Random Primers, 1 μl MultiScribe Reverse Transcriptase (50 U/μl), 1 μl
RNase Inhibitor and 3.2 μl nuclease-free water. The reaction was then incubated at 25ºC for
10 minutes, followed by 37ºC for 2 hours and 85ºC for 5 seconds to inactivate the activities
of the reverse transcriptase and to completely denature the template.
2.6 qPCR
The procedure for qPCR was followed as described elsewhere [8, 9]. In brief, qPCR was
performed using cDNA of each sample, gene-specific primers (Table 1) and Platinum SYBR
Green qPCR SuperMix-UDG (Invitrogen), according to the protocol from the manufacturer.
The reactions were run for 50 cycles at 94ºC for 10 minutes, 95ºC for 90 seconds and 72ºC
for 90 seconds in an ABI PRISM 7700 Sequence Detector (Applied Biosystems). Cycle
threshold (CT) values of each reaction were obtained using Sequence Detection System(SDS) Software Version 1.9.1. For each reaction, the expression of each gene was
normalized against the expression of the housekeeping gene β-actin. The relative
expression of each gene was calculated based on a comparative CT equation and ispresented as the value of relative intensity.
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Table 1. Primer sequences of studied genes
Gene DNA sequences
HMGA2 5’-CAGCAGCAAGAACCAACC-3’
5’-CAGTTTCCTCCTGAGCAG-3’
PEG10 5’-GGGTCTGTCATCGACTAC-3’
5’-CTCGGTTGGATCTACCTG-3’
SHANK2 purchased from SuperArray Bioscience Corporation
(Frederick, MD, USA)
WISP3 5’-CAGCAGCTTTCAACAAGCTACA-3’
5’-TTCCCATCCCACATGTTCTG-3’
β-Actin 5’-GCTCGTCGTCGACAACGGCTC-3’
5’-CAAACATGATCTGGGTCATCTTCTC-3’
2.7 Statistical Analysis for qPCR Data
Statistical analysis was performed as described elsewhere [10]. One-way ANOVA followed
by Duncan’s multiple range test was used to determine statistical significance. Each sample
was run in triplicates. The relative value is presented as the mean ± standard error of the
mean (S.E.M.). p-Values less than 0.05 were considered statistically significant. Statistical
analysis was performed with Statistical Package for the Social Sciences version 17 (IBM,
New York, USA).
2.8 Immunohistochemistry
Immunohistochemistry was performed using the avidin-biotin method [11, 12]. Five-
micrometer paraffin sections were prepared on gelatin-coated glass slides. Sections were
preheated at 60ºC for 20 minutes, deparaffinized in xylene and rehydrated through graded
alcohol. Antigen retrieval was carried out by heating the sections in 0.2 M citrate buffer (pH
6) in a microwave oven at 95ºC for 5 minutes. After cooling for 30 minutes, the sections were
treated with 0.3% hydrogen peroxide at room temperature for 30 minutes to block
endogenous peroxidase activity. Non-specific binding sites on sections were blocked with 1X
TBS with 2% bovine serum albumin (BSA; Sigma-Aldrich, St Louis, MO, USA) and 2%
normal goat serum (Invitrogen) at room temperature for 30 minutes. HMGA2-specific rabbit
polyclonal antibody (1:100) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was applied
to the sections and the reaction was incubated at room temperature for 30 minutes. After
washing three times with 1X TBS for 5 minutes each, the sections were incubated with
biotinylated anti-rabbit secondary antibody (EnVision Systems; Dako, Glostrup, Denmark) at
room temperature for 30 minutes. To visualize the signals, the sections were washed and
stained with avidin-biotin complex and 3, 3’-diaminobenzene (DAB) at room temperature.
Lastly, the sections were counterstained with hematoxylin. The expressions of HMGA2 were
evaluated by Dr. AK Lam, a qualified pathologist, under light microscope.
3. RESULTS
3.1 Identification of Differentially Expressed Genes Using Gene Microarray
Gene microarray analysis revealed 3,081 genes, 4,027 genes and 3,590 genes having more
than 2-fold induction in T, LN and HKESC-4 cells when compared to N. For down-regulated
genes with more than 2-fold difference, 4,808 genes, 6,052 genes and 5,846 genes were
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found in T, LN and HKESC-4 cells in comparison with N. For those up-regulated genes in T,
LN and HKESC-4, 43 of them had more than 10-fold induction (Table 2). Among them, 34
genes (CAMK2A, CART1, CCNA1, COCH, FLJ33516, FMN2, FOXD1, FOXG1B, GPR,
HMGA2, HOXC10, HOXC11, HTR2C, IMP-3, LOC163782, MAGEB2, MFAP2, MGC17986,
MGC27005, NBEA, NKX2-2, PCDHB5, PEG10, PFN2, POPDC3, PPFIA1, PRAME, SAGE1,
SHANK2, SIX1, SLCO1B3, SYT1, TP53TG3 and WISP3) were first identified to be
overexpressed in ESCC, while 13 of them (DKK1, EGFR, EMS1, GAL, HCG4, LAMC2,
MAGEA1, MAGEA4, MAGEA11, MMP13, PTHLH, ZIC and ZNF595) have previously been
reported to be overexpressed in ESCC (Table 3). Among the 34 newly identified genes,
HMGA2, PEG10, SHANK2 and WISP3 were further selected for validation due to their
potential involvement in tumorigenesis based on literature search.
3.2 Gene Expression of HMGA2
High expression of HMGA2 in N, T, LN and HKESC-4 observed in gene microarray was
confirmed using qPCR, such that the relative intensities of HMGA2 expression in N, T, LN
and HKESC-4 obtained using these two methods were comparable (fold change by gene
microarray: 1, 31, 63 and 18 versus 1, 26, 49 and 33 by qPCR). Moreover, increased gene
expression of HMGA2 was also detected in four ESCC cell lines (HKESC-1, HKESC-2,
HKESC-3 and SLMT-1). Significantly higher gene expression on average of 20-fold of
HMGA2 was noted in ESCC cell lines when compared to N and Non-T (Fig. 1A).
3.3 Gene Expression of PEG10
An over-expression of PEG10 in ESCC observed in gene microarray was confirmed using
qPCR. The relative intensities of PEG10 in N, T, LN and HKESC-4 cells were 1, 20, 28 and
28 by gene microarray, while their relative intensities were 1, 45, 148 and 269 by qPCR,
respectively. However, no significant difference in the average gene expression of PEG10
was detected in tested ESCC cell lines when compared to N and Non-T, despite their having
an average of 100-fold induction in gene expression of PEG10 (Fig. 1B).
3.4 Gene Expression of SHANK2
High gene expression of SHANK2 in ESCC observed in gene microarray was confirmed
using qPCR. The relative intensities of SHANK2 in N, T, LN and HKESC-4 cells were 1, 30,
20 and 20 by gene microarray and 1, 21, 11 and 19 by qPCR, respectively. No significant
difference in the gene expression of SHANK2 was detected in ESCC cells when compared
to N (Fig. 1C).
3.5 Gene Expression of WISP3
High gene expression of WISP3 in ESCC detected using gene microarray was confirmed
using qPCR. The relative intensities of gene expression of WISP3 in N, T, LN and HKESC-4
cells were 1, 37, 53 and 26 by gene microarray and 1, 152, 117 and 117 by qPCR,
respectively. A significant increase in the gene expression of WISP3 was detected in
HKESC-2 cells (Fig. 1D).
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3.6 Protein Expression of HMGA2 in ESCC Tissues
Immunohistochemical data show the localization of HMGA2 in the nuclei of the ESCC
tissues (Fig. 2). Overexpression of HMGA2 was found in 70% ESCC tissues (21 out of 30
cases) when the expression of HMGA2 was examined in 30 pairs of tumoral tissues and
adjacent non-tumoral tissues. No detectable level of HMGA2 expression was observed in
the non-tumoral tissues (data not shown).
Table 2. Genes with >10-fold expression difference in esophageal squamous cell
carcinoma tissues and cells
Relative intensity*
Gene symbol Position Chromosome
location
Tumor Lymph node
metastasis
HKESC-4
cells
CAMK2A 229163_at 1p36.13 24.08 17.26 20.94
CAMK2A 218309_at 1p36.13 22.7 17.76 23.08
CAMK2A 228302_x_at 1p36.13 17.06 11.62 28.18
CART1 206837_at 12q21.3-q22 16.01 15.6 14.43
CCNA1 205899_at 13q12.3-q13 50.35 58.86 48.36
COCH 205229_s_at 14q12-q13 14.14 13.1 11.59
DKK1 204602_at 10q11.2 64.93 96.28 344.8
EGFR 201984_s_at 7p12 22.85 31.67 30.82
EMS1 214073_at 11q13 17.43 17.63 21.22
FLJ33516 229160_at Xq22.3 18.6 53.55 32.52
FMN2 223618_at 1q43 16.56 22.98 22.86
FMN2 1555471_a_at 1q43 11.93 14.46 17.5
FOXD1 206307_s_at 5q12-q13 15.44 20.53 13.95
FOXG1B 206018_at 14q12-q13 18.82 24.46 30.44
GAL 214240_at 11q13.1 41.56 46.58 41.16
GPR 227846_at 15q14 12.91 11.44 13.84
HCG4 206685_at 6p21.3 11.44 21.18 7.994
HMGA2 208025_s_at 12q15 31.22 62.65 17.94
HOXC10 218959_at 12q13.3 22.96 22.56 31.13
HOXD10 229400_at 2q31.1 13.15 15.05 21.27
HOXD11 214604_at 2q31.1 20.12 26.2 23.37
HTR2C 207307_at Xq24 21.95 18.02 26.57
IMP-3 203820_s_at 7p11 21.56 35.95 30.82
LAMC2 202267_at 1q25-q31 21.33 28.72 11.3
LOC163782 229125_at 1p32.1 14.43 11.71 39.89
MAGEA1 207325_x_at Xq28 89.08 192.8 129.5
MAGEA11 210503_at Xq28 36.73 43.59 25.86
MAGEA4 214254_at Xq28 30.04 47.19 28.42
MAGEB2 206218_at Xp21.3 101.3 111.9 113.1
MFAP2 203417_at 1p36.1-p35 47.36 25.34 14.93
MGC17986 1552946_at 19q13.33 19.44 21.97 18.82
MGC27005 1567912_s_at --- 345.1 662 441.5
MGC27005 235700_at Xq26.3 227.8 410.3 305.3
MMP13 205959_at 11q22.3 206.5 82.06 46.82
NBEA 239010_at --- 24.72 19.12 21.34
NKX2-2 206915_at 20pter-q11.23 20.36 20.32 19.78
PCDHB5 223629_at 5q31 13.68 19.72 25.47
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PEG10 212094_at 7q21 19.58 27.79 27.8
PFN2 204992_s_at 3q25.1-q25.2 14.39 20.15 17.83
POPDC3 219926_at 6q21 20.75 26.54 28.86
PPFIA1 210236_at 11q13.2 14.19 17.12 15.62
PRAME 204086_at 22q11.22 11.47 17.7 13.24
PTHLH 1556773_at 12p12.1-p11.2 42.7 120.4 67.42
PTHLH 206300_s_at 12p12.1-p11.2 41.34 76.86 48.18
PTHLH 211756_at 12p12.1-p11.2 35.64 76 34.72
SAGE1 220793_at Xq26 15.89 20.5 56.04
SHANK2 213308_at 11q13.2 29.9 19.83 19.99
SHANK2 213307_at 11q13.2 19.41 14.38 15.04
SIX1 228347_at 14q23.1 20.37 23.38 19.25
SLCO1B3 206354_at 12p12 13.48 27.82 30.46
SYT1 203999_at 12cen-q21 21.44 20.41 21.4
TP53TG3 220167_s_at 16p13 16.8 12.91 10.12
WISP3 210861_s_at 6q22-q23 36.77 52.97 26.4
ZIC1 206373_at 3q24 61.6 70 97.5
ZNF595 227952_at --- 20.42 39.94 31.02
* Relative to morphologically normal esophageal epithelium
Table 3. Genes found to have overexpression in ESCC in previous studies
Gene Symbol Description Reference
DKK1 Overexpression of DKK1 gene in the distal squamous
esophageal mucosa in patients with esophagitis
[13]
EGFR Overexpression of EGFR in ESCC and its correlation
with depth of tumor invasion
[14]
EMS1 Association of amplification and overexpression of
EMS1 with lymph node metastasis in ESCC
[15]
GAL Distribution of galanin (GAL) immunoreactive nerve
bundles and scattered nerve fibres in esophageal
carcinoma
[16]
HCG High expression of HCG expression in patients with
lymph node metastasis and its correlation with
infiltration and metastasis
[17]
LAMC2 Co-expression of LN-5 gamma2 (LAMC2) and EGFR is
closely related to the progression and poor prognosis
of ESCC
[18]
PTHLH High level of serum parathyroid hormone-related
protein (PTHLH) in esophageal carcinoma
[19]
MAGE-A,
MMP13,
ZNF595
High expression of MAGE-A, MMP13 and zinc finger
proteins in ESCC
[20]
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Fig. 1. Gene expressions of HMGA2 (A), PEG10 (B), SHANK2 (C) and WISP3 (D)
relative to β-actin have been shown in clinical tissues and ESCC cell lines. The value
of N is arbitrarily set to 1 for comparison
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Fig. 2. Immunohistochemical staining of HMGA2 in ESCC tissues. Original
magnification, 200X (A, C and E); 400X (B, D and F)
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4. DISCUSSION
In the present study, to our knowledge, the gene microarray and real-time qPCR analysis
showed the presence of HMGA2 mRNA expression in human esophageal tissues for the first
time. HMGA2 mRNA overexpression was detected in ESCC cell lines compared with the
corresponding morphologically non-tumoral esophageal epithelial tissues. The current
findings showed that overexpression of HMGA2 gene appears to be a consistent feature in
ESCC. The protein expression of HMGA2 was further validated in ESCC specimens by
immunohistochemistry. Liu et al. have shown an elevated level of HMGA2 protein in ESCC
tissues by comparing 150 pairs of tumor and adjacent non-tumor tissues in patients [21], for
which this data are in line with our findings reported here. The immunostaining analysis
showed that HMGA2 protein expression was localized in the nuclei of the ESCC cells. The
majority of ESCC cases (21/30, 70%) were found to have significantly enhanced expression
of HMGA2 compared with morphologically normal esophageal epithelium.
HMGA2 belongs to the HMGA family, which also contains two other members HMGA1A and
HMGA1B. HMGA protein family members are small nuclear proteins. A prominent feature of
the HMGA family is the three DNA-binding domains termed AT-hooks at the N-terminal
region that bind the minor groove of AT-rich DNA sequences. These proteins play key roles
in chromatin architecture and gene control by serving as generalized chromatin effectors,
either enhancing or suppressing the ability of transcriptional factors in the process of
transcriptional regulation. HMGA2 expression was found to be restricted during
embryogenesis, whereas it is absent or has low expression in normal adult tissues [22].
However, over expression of HMGA2 has been reported in various types of human cancer
including of the pituitary [23], oral cavity [24], lung [25], breast [26], pancreas [27], and
nerves [28]. In addition, HMGA2 protein was reported to be ectopically expressed at the
invasive front of oral carcinomas and had a significant impact on tumor progression and
patient survival [24]. Similarly, HMGA proteins were found to be expressed in lung
carcinomas and their expressions were inversely associated with survival, providing a
potentially useful marker for diagnosis and prognosis of lung cancer [29].
Overexpression of HMGA2 gene leads to pituitary adenomas in mice. The mechanism has
been described by Fedele et al. [30]. HMGA2 binds to the pRB A/B pocket domain, while it
does not compete with the E2F1 protein. Conversely, E2F1 activation by HMGA2 occurs by
displacing HDAC1 from the pRB/ E2F1 complex, resulting in enhanced acetylation of both
E2F1 and DNA-associating histones, thereby promoting E2F1 activation [30]. It is well-
known that pRB controls cell cycle progression through its interaction with the E2F family of
transcription factors, whose activity is crucial for the expression of several genes required for
cells to enter the S phase of the cell cycle [31]. By repressing E2F1 activity, pRB protein
prevents cell from progressing beyond the G1 phase of the cell cycle. If the repression of
E2F1 is relieved by phosphorylation or viral transformation of pRB [32, 33], resulting in the
release of E2F1, the transcription of its target genes is activated [34]. This allows cells to
progress toward S phase. The overexpressions of pRB [35] and E2F1 [36] were also found
in ESCC specimens. These findings are consistent with the mechanism in pituitary cancer
described by Fedele et al. [22]. This suggests that the pRB/E2F1 pathway involving HMGA2
may also play a critical role in the pathogenesis of ESCC.
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5. CONCLUSION
In summary, the gene microarray results show a comprehensive picture of the differential
gene expression in ESCC. Thirty-four novel overexpressed genes were revealed in this
study. The real-time qPCR results confirmed that HMGA2 was up-regulated in all the ESCC
cell lines examined. In addition, the protein expression of HMGA2 demonstrated a
significantly higher incidence of overexpression in primary ESCCs than morphologically non-
tumoral esophageal epithelium tissue. For the first time, the present findings showed that
HMGA2 was overexpressed in ESCC, and suggest that the activation of HMGA2 might be
important in the pathogenesis of ESCC.
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